retatrutide clinical trials status 2025 Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial This data from Phase 3
Description
Early clinical results suggest the treatment is safe and well tolerated.
Retatrutide produces the greatest weight loss (up to 24.2%), followed by tirzepatide (up to 22.5%), then semaglutide (up to 14.9%), but retatrutide remains i...
Eric Topol nails ittheres a huge evidence gap between GLP-1 peptides and virtually all others
Refrigerated (2C 8C)
Here's what's behind changes to your monthly flow on this Rx
Medicare is now covering weight loss drugs for some people
